Glucovance (Metformin Hydrochloride, Glibenclamide)

Glucovance is indicated for the management of hyperglycemia in patients with type 2 diabetes mellitus, typically when diet, exercise, and monotherapy have not achieved target glucose levels.

• As an adjunct to lifestyle modification to improve overall glycemic control.
• In combination with other oral antidiabetic agents when additional glucose lowering is required.
• For patients who need both decreased hepatic glucose output and increased insulin secretion.
• To help achieve individualized HbA1c goals as part of a comprehensive diabetes management plan.
• When renal function is stable and the patient does not have contraindications to either component, Glucovance may be considered as a single‑tablet regimen.

The safety profile of Glucovance reflects the combined actions of metformin and glibenclamide, producing a range of adverse events that are reported with varying frequency.

Common

• Gastrointestinal discomfort such as nausea, abdominal pain, or diarrhea.
• Mild hypoglycemia, especially when meals are skipped or delayed.
• Metallic taste in the mouth.
• Weight gain or fluid retention.
• Headache or mild dizziness.
• Decreased appetite or early satiety.

Serious

• Lactic acidosis, a rare but life‑threatening condition associated with metformin accumulation.
• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions including skin rash, itching, or swelling of the face and throat.
• Pancreatitis presenting with severe abdominal pain.

When prescribing Glucovance, clinicians should evaluate patient history and monitor for conditions that may increase the risk of adverse outcomes.

• Assess renal function before initiation and periodically thereafter, as impaired clearance can raise metformin levels.
• Use caution in patients with hepatic impairment, heart failure, or a history of lactic acidosis.
• Avoid use in pregnant women unless the potential benefit outweighs risk; the drug is classified as pregnancy category C.
• Monitor blood glucose closely to prevent hypoglycemia, especially when dietary intake changes.
• Discontinue or adjust dose before any radiographic procedures that use iodinated contrast agents.
• Educate patients on recognizing signs of hypoglycemia and lactic acidosis.

Glucovance may interact with other medicines, altering its effectiveness or increasing the risk of side effects.

Avoid

• Iodinated contrast agents administered intra‑arterially or intravenously, which can precipitate metformin‑associated lactic acidosis.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that increase glibenclamide plasma concentrations.
• Other sulfonylureas or meglitinides, which can cause additive hypoglycemia.

Use with caution

• Renal‑impairing drugs such as ACE inhibitors, NSAIDs, or diuretics; monitor kidney function and adjust dose if needed.
• Beta‑blockers, which may mask hypoglycemia symptoms.
• Alcohol consumption, which can potentiate metformin’s effect on lactate metabolism.
• Thyroid hormones, as altered metabolism may affect glucose control.